Literature DB >> 9337287

Multimodality therapy for esophageal cancer.

A A Forastiere1, R F Heitmiller, L Kleinberg.   

Abstract

Over the past decade and a half, several strategies have been developed to improve the survival of patients with esophageal cancer. Two strategies employ either neoadjuvant chemotherapy or chemoradiotherapy followed by surgery to improve local-regional control and decrease the incidence of distant metastases. A third strategy uses nonsurgical therapy as definitive treatment for patients without metastatic disease. Single-institution pilot trials and randomized comparative trials have been conducted evaluating each approach. The rationale for these trials, results, and current recommendations are presented.

Entities:  

Mesh:

Year:  1997        PMID: 9337287     DOI: 10.1378/chest.112.4_supplement.195s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary?

Authors:  Carlo Castoro; Marco Scarpa; Matteo Cagol; Rita Alfieri; Alberto Ruol; Francesco Cavallin; Silvia Michieletto; Giampietro Zanchettin; Vanna Chiarion-Sileni; Luigi Corti; Ermanno Ancona
Journal:  J Gastrointest Surg       Date:  2013-08       Impact factor: 3.452

2.  The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.

Authors:  Grace J Kim; Matthew Koshy; Alexandra L Hanlon; M Naomi Horiba; Martin J Edelman; Whitney M Burrows; Richard J Battafarano; Mohan Suntharalingam
Journal:  Am J Clin Oncol       Date:  2016-04       Impact factor: 2.339

3.  Treatment results of preoperative concurrent chemoradiotherapy followed by surgery for stage III or IV esophageal squamous cell carcinoma.

Authors:  Hideomi Yamashita; Keiichi Nakagawa; Masao Tago; Naoki Nakamura; Kenshiro Shiraishi; Ken-ichi Mafune; Michio Kaminishi; Kuni Ohtomo
Journal:  Radiat Med       Date:  2006-01

4.  Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response?

Authors:  Robert A Meguid; Craig M Hooker; Joshua T Taylor; Laurence R Kleinberg; Stephen M Cattaneo; Marc S Sussman; Stephen C Yang; Richard F Heitmiller; Arlene A Forastiere; Malcolm V Brock
Journal:  J Thorac Cardiovasc Surg       Date:  2009-12       Impact factor: 5.209

5.  Preferred location for the development of esophageal adenocarcinoma within a segment of intestinal metaplasia.

Authors:  J Theisen; H J Stein; M Feith; W K H Kauer; H J Dittler; D Pirchi; J R Siewert
Journal:  Surg Endosc       Date:  2005-12-28       Impact factor: 3.453

6.  Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer.

Authors:  V Chiarion-Sileni; L Corti; A Ruol; R Innocente; C Boso; P Del Bianco; J Pigozzo; R Mazzarotto; O Tomassi; E Ancona
Journal:  Br J Cancer       Date:  2007-01-23       Impact factor: 7.640

7.  The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma.

Authors:  M Sarbia; M Stahl; C von Weyhern; G Weirich; F Pühringer-Oppermann
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.